SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates

Every plan includes:

✓Signal-Driven Leads Based on YOUR ICP

✓Slack + Chrome real-time alerts

✓No duplicates — only new events

INDUSTRY FIRST

Ocudyne, Inc. announced it raised $463,000 in an initial filing from an offering of $500,000

Oct 20, 2016•almost 9 years ago

Amount Raised

$463,000

Round Type

seed

Brooklyn ParkHealth Care

Company Information

Company

Ocudyne

Location

7600 Boone Avenue North, Suite #7

Brooklyn Park, Minnesota, United States

About

OcuDyne is a clinical-stage medical device company developing a novel therapy to treat Age Related Macular Degeneration (AMD), the leading cause of irreversible vision loss in the elderly worldwide. As a world leader in the evaluation of ocular perfusion and how it influences ocular health, OcuDyne’s mission is to develop therapies that improve blood flow to the eye. Impaired blood flow causes disease in organ systems all over the body, and the eye is no exception. Over the past few years, advances in intracranial and arterial imaging have shown that impared ocular perfusion is present in patients suffering from AMD. As a result, AMD is the first indication being pursued by OcuDyne.

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech